Male or female subjects greater than 18 years old, inclusive.
Pathologically confirmed diagnoses of Relapsed or resistant AML or ALL.
Patients who are ineligible for standard therapies that are anticipated to result in durable remission or cure, or who have no known therapy options of documented benefit.
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
You may not be if
Concomitant chemotherapy, radiation therapy, or immunotherapy.
Receiving any other investigational agents concurrently or within 30 days prior to screening.
Patient has acute promyelocytic leukaemia or leukemia with active CNS involvement.
History of another active malignancy with 2 years prior to study entry, basal cell skin cancer and previous carcinoma in treated curatively.
Patient with mental deficits and/or psychiatric history that precludes them from giving informed consent or from following protocol.
Clareo Health | The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
